Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elizabeth Mills

Showing results (21-30 of 21) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 21 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2010
AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor, ERBB2 (HER2), and ERBB3: a unique agent for simultaneous ERBB receptor blockade in cancerD Mark Hickinson, Teresa Klinowska, Georgina Speake, et al.
Pageof 3

Showing results (21-30 of 21) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 21 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2010
AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor, ERBB2 (HER2), and ERBB3: a unique agent for simultaneous ERBB receptor blockade in cancerD Mark Hickinson, Teresa Klinowska, Georgina Speake, et al.
Pageof 3